Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer
Background: The prognostic relevance of uncommon epithelial ovarian cancer (EOC)
histological subtypes remains controversial. The Gynecologic Cancer InterGroup (GCIG) …
histological subtypes remains controversial. The Gynecologic Cancer InterGroup (GCIG) …
Clinical trials in recurrent ovarian cancer
M Friedlander, E Trimble, A Tinker, D Alberts… - International Journal of …, 2011 - ijgc.bmj.com
The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …
held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research …
Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy
C Gourley, J Balmaña, JA Ledermann… - Journal of Clinical …, 2019 - discovery.ucl.ac.uk
The DNA damage response (DDR) pathway coordinates the identification, signaling, and
repair of DNA damage caused by endogenous or exogenous factors and regulates cell …
repair of DNA damage caused by endogenous or exogenous factors and regulates cell …
[HTML][HTML] A phase 3 trial of bevacizumab in ovarian cancer
TJ Perren, AM Swart, J Pfisterer… - … England Journal of …, 2011 - Mass Medical Soc
Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …
Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 …
BACKGROUND: Primary surgery followed by platinum‐taxane based chemotherapy has
been the standard therapy in advanced ovarian cancer. However, the prognostic role of …
been the standard therapy in advanced ovarian cancer. However, the prognostic role of …
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
E Pujade-Lauraine, F Hilpert, B Weber… - Obstetrical & …, 2014 - journals.lww.com
Standard therapy for platinum-resistant ovarian cancer (OC) is single-agent chemotherapy.
The most active single agents are pegylated liposomal doxorubicin, paclitaxel, and …
The most active single agents are pegylated liposomal doxorubicin, paclitaxel, and …
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind …
E Pujade-Lauraine, JA Ledermann, F Selle… - The lancet …, 2017 - thelancet.com
Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …
[HTML][HTML] Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
Background Olaparib has shown significant clinical benefit as maintenance therapy in
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
women with newly diagnosed advanced ovarian cancer with a BRCA mutation. The effect of …
[PDF][PDF] Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2 …
T Bachelot, C Bourgier, C Cropet… - Journal of Clinical …, 2012 - arcagy.org
Purpose Cross-talk between signal transduction pathways likely contributes to hormone
resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian …
resistance in metastatic breast cancer (mBC). Everolimus, an oral inhibitor of the mammalian …
[HTML][HTML] Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 …
AM Oza, AD Cook, J Pfisterer, A Embleton… - The Lancet …, 2015 - thelancet.com
Background The ICON7 trial previously reported improved progression-free survival in
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …
women with ovarian cancer with the addition of bevacizumab to standard chemotherapy …